Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:40 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis

NCT03540485 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · PHASE1/PHASE2 · terminated · last registry update 2026-02-20 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“Early termination due to operational feasibility reasons, resulting from a slow recruitment rate and logistical and financial difficulties that prevent reaching the planned sample size within the study schedule.”	–	Registry record, Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against MTNR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision